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Summary
We have targeted a K-ras allele in mouse embryonic stem (ES) cells to express a K-RasV12 oncoprotein along with a marker
protein (-geo) from a single bicistronic transcript. Expression of this oncogenic allele requires removal of a knocked in
STOP transcriptional cassette by Cre recombinase. Primary mouse embryonic fibroblasts expressing this K-rasV12 allele
do not undergo proliferative senescence and proliferate as immortal cells. In mice, expression of K-rasV12 throughout the
body fails to induce unscheduled proliferation or other growth abnormalities for up to eight months. Only a percentage of
K-rasV12-expressing lung bronchiolo-alveolar cells undergo malignant transformation leading to the formation of multiple
adenomas and adenocarcinomas. These results indicate that neoplastic growth induced by an endogenous K-ras oncogene
depends upon cellular context.
Introduction breast tumors (Bos, 1989). The molecular bases for these varia-
tions are unknown. Moreover, its relative contribution to tumor
Ras genes are some of the most widely studied cancer-related development is still obscure. Whereas in colon adenocarcino-
genes due to their frequent activation in human tumors. These mas activation of K-ras oncogenes is an early but not an initiating
prototypic small GTPases act as molecular switches that trans- event, in other tumors, activation of K-ras oncogenes can be a
fer information from the membrane to the nucleus. Some of their late event, sometimes associated with invasive or metastatic
upstream activators include receptor and nonreceptor tyrosine processes (Bos, 1989).
protein kinases and, to a lesser extent, G protein-coupled recep- Unveiling the precise role of ras oncogenes in the develop-
tors. Downstream, Ras proteins interact with multiple effector ment of human cancer is hindered by the sporadic nature of
pathways. The best studied are those involved in mitogenic their activation and by the fact that tumors grow undetected
for several years. The possibility to manipulate the mouse ge-signaling, the Raf/Mek/Erk pathway, and in survival, the phos-
phoinositol-3 kinase (PI3K)/Pdk/Akt pathway. The structure of nome has opened new opportunities to develop tumor models
that recapitulate more closely those events responsible for theRas proteins, both alone and associated with some of their
downstream effectors, has been resolved, thus opening new human disease (Fisher et al., 2001; Jackson et al., 2001; John-
son et al., 2001; Meuwissen et al., 2001). In this study, weopportunities for rational drug discovery (Downward, 2003; Vet-
ter and Wittinghofer, 2001). describe gene-targeted mice in which expression of an endoge-
nous K-ras oncogene, engineered by a knockin strategy, canAmong ras oncogenes, K-ras is the most frequently acti-
vated in human tumors. However, its incidence varies widely. be activated with synthetic steroids at any time and in any
tissue. More importantly, expression of this oncogene can beWhereas K-ras oncogenes are found in almost 90% of pancre-
atic cancers, they are present in 50% of colon and 25% of monitored by coexpression of a bicistronic color marker. These
mice have allowed us to illustrate that wide expression of anlung adenocarcinomas and basically absent from prostate and
S I G N I F I C A N C E
Gene-targeted mice described here allow us to monitor the fate of cells expressing an endogenous K-ras oncogene in somatic
cells. Unexpectedly, most K-ras oncogene-expressing cells remain normal for long periods of time (up to eight months), including
stem cells that retain their capacity to proliferate and differentiate to form hair follicles in the dermis or intestinal crypts. Only lung
bronchiolo-alveolar cells acquire hyperproliferative properties and progress into malignant adenocarcinomas. These observations
establish the experimental bases to identify those pathways that convey resistance or permissiveness to K-ras transformation within
a physiological context. In addition, this work illustrates that an endogenous K-ras oncogene, when expressed at physiological
levels, does not induce senescence due to oncogenic stress in mouse embryonic fibroblasts (MEFs). Instead, expression of the
endogenous K-ras oncogene overrides proliferative senescence, a characteristic of immortal cells.
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Figure 1. Gene targeting strategy
A: Homologous recombination at the 3 region
of the K-ras locus. K-ras 4B exon: Black, coding
sequences; white, noncoding sequences; dark
gray, polyadenylation sequences. Light gray,
IRES--geo cassette. The location of the probe
used in the Southern blot analysis is indicated.
Representative restriction enzyme cleavage sites
are indicated (H, HindIII; X, XbaI; S, SalI).
B: Southern blot analysis of DNA isolated from
(WT) wild-type and (HR) clones carrying the ex-
pected homologous recombination event after
digestion with HindIII. The size of the wild-type (6.5
kbp) and targeted (10.5 kbp) alleles is indicated.
C: Homologous recombination at the 5 region
of the K-ras locus. White box, K-ras noncoding
exon 0; black box, K-ras coding exon 1; Hyg,
PGK-Hygromycin cassette; STOP, transcriptional
inhibitory sequences; triangle, loxP sites; *, onco-
genic mutation in codon 12. The position of the
probe used in the Southern blot analysis is indi-
cated. Representative restriction enzyme cleav-
age sites are indicated (X, XbaI; E, EcoRI; V,
EcoRV; N, NotI).
D: Southern blot analysis of DNA isolated from
wild-type (WT) and clones (HR) carrying the ex-
pected homologous recombination event after
digestion with XbaI. The size of the wild-type (5
kbp) and targeted (3.5 kbp) alleles is indicated.
endogenous K-ras oncogene has no consequences in most first exon with sequences carrying a mutant codon 12 encoding
tissues and/or cell types, thus indicating that tumor develop- a valine residue, a mutation frequently found in human tumors
ment is highly dependent on cellular context. Moreover, charac- (Bos, 1989). In this recombination event, we also inserted within
terization of mouse embryonic fibroblasts (MEFs) derived from the first intron transcriptional STOP sequences (Lakso et al.,
these mice reveals that expression of a K-ras oncogene at physi- 1992) and a PGK-Hygro cassette flanked by loxP sites (Figure
ological levels induces cellular immortalization instead of senes- 1C). Seven out of 96 hygromycin-resistant clones tested (7%)
cence (Serrano et al., 1997). displayed the expected recombination event (Figure 1D).
Targeted ES cells carrying the two recombination events
Results within the same K-ras allele (about 50% of the clones) were
identified by their ability to express the -geo marker only upon
transfection with Cre recombinase. These cells expressed theTargeting strategy
We have targeted mouse embryonic stem (ES) cells to generate targeted K-ras mRNA as determined by RT-PCR analysis fol-
lowed by digestion with a diagnostic SfcI restriction endonucle-an oncogenic K-ras allele whose expression can be induced and
monitored in vivo. To this end, we introduced by homologous ase as described in Figure 2. Selected clones were submitted
to cytogenetic analysis and those that exhibited a normal karyo-recombination an IRES--geo cassette within the 3 untrans-
lated region of a K-ras allele (Friedrich and Soriano, 1991) (Figure type (MCG537 and MCG758) were used to generate chimeric
mice by microinjection into C57BL/6 blastocysts. Chimeric male1A). The internal ribosomal entry site (IRES) allows bicistronic
translation of -geo sequences from a transcript driven by the mice were backcrossed to C57BL/6 females and germline trans-
mission of the targeted allele scored by Southern blot analysisendogenous K-ras promoter (Mountford et al., 1994). G418 re-
sistant clones were submitted to Southern blot analysis to iden- of tail DNA from the agouti offspring. Heterozygous K-ras/V12
mice were born at the expected Mendelian ratios. These animalstify those that had undergone the expected recombination event
(Figure 1B). We obtained a high percentage of homologous do not show obvious abnormalities. X-Gal analysis of embryos
and tissues derived from heterozygous K-ras/V12 mice doesrecombinant clones (134/192, 70%), most likely due to the lack
of an internal promoter in the IRES--geo cassette. As expected, not reveal cells expressing the -geo marker. Homozygous
K-rasV12/V12 embryos die at midgestation with a phenotype similarall G418 resistant clones were positive for X-Gal staining (data
not shown). Two clones (MCG224 and MCG231) were selected to that described for K-ras/ mice (Johnson et al., 1997), indi-
cating that the knocked in transcriptional STOP sequences ef-for a second recombination event in the 5 end of the same K-ras
allele. This targeting event allowed us to replace the endogenous fectively prevent expression of the K-rasV12 allele.
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expression, presumably due to partial excision of the floxed
STOP transcriptional sequences. Thus, we treated K-ras/V12;
CMV-Cre/T MEFs with G418 for five days to eliminate those
cells not expressing K-rasV12 transcripts.
In addition, we generated MEFs in which the K-rasV12 allele
is transcriptionally activated in vitro. To this end, we crossed
K-ras/V12 animals with RERTn mice (Figure 3), a knockin strain
that expresses the inducible Cre-ERT2 recombinase (Brocard
et al., 1997) under the control of the locus encoding the large
subunit of RNA polymerase II (V.C., N.M., C.G., and M.B., un-
published data). We treated the resulting K-ras/V12;RERTn/ERT
MEFs for six days with 4-hydroxy-tamoxifen (4-OHT) to activate
the inducible Cre-ERT2 recombinase and with G418 for five
additional days to select for -geo cells. The resulting K-ras/V12;
RERTn/ERTOHT MEFs uniformly express the -geo marker.
MEFs that only express the wild-type K-ras allele, including
K-ras/V12, K-ras/;CMV-Cre/T and K-ras/V12;RERTn/ERT MEFs,
undergo crisis, also known as proliferative senescence, after
few passages in culture (Figure 4A). Upon continuous passage,
these MEFs become immortal following the same kinetics as
K-ras/ MEFs. In contrast, MEFs expressing the oncogenic
K-ras/V12 allele, including K-ras/V12;CMV-Cre/T and K-ras/V12;
RERTn/ERTOHT MEFs, do not undergo proliferative senescence
and proliferate continuously as immortal cells (Figure 4A).
Signaling pathways
Proliferating primary K-ras/V12;CMV-Cre/T MEFs contain lower
steady-state levels of phosphorylated Erk1/2 proteins than
control K-ras/ or K-ras/V12 MEFs. However, these MEFs ex-
hibit a similar Erk1/2 phosphorylation response upon EGF treat-
ment (Figure 4B). On the other hand, serum-starved primary
K-ras/V12;CMV-Cre/T MEFs display a more sustained Erk1/2
phosphorylation in response to EGF than control MEFs (Figure
4C). Sustained activation of the Erk pathway has been associ-
ated with cell cycle arrest (Marshall 1995; Agell et al., 2002). How-
ever, transient activation of Erk is not sufficient to induce prolifera-
tion (Balmanno and Cook, 1999). Moreover, activation of Erk by
a constitutively active MAP kinase kinase (Mek1) induces differenti-
ation of PC12 cells but transformation of NIH3T3 cells (Cowley
Figure 2. Expression of wild-type and oncogenic K-ras alleles et al., 1994). Thus, the precise levels and duration of Erk1/2
phosphorylation required to elicit specific cellular responsesA: Schematic representation of the RT-PCR strategy used to identify tran-
scripts from (WT) wild-type K-ras and (V12) oncogenic K-rasV12 alleles. White may vary in different cell types. Our results suggest that the sus-
boxes, K-ras transcripts. Numbers indicate exons. Gray box, IRES--geo se- tained activation of Erk1/2 induced by the endogenous K-rasV12
quences present in K-rasV12 transcripts. Translational initiator (ATG) and termi-
oncogene may be at least partially responsible for the observednator (TGA) codons, (pA) polyadenosine tail, (V12) oncogenic mutation,
loss of proliferative senescence of K-ras/V12;CMV-Cre/T MEFs.and sizes of the RT-PCR products before and after SfcI (S) digestion are
indicated. We also observed prolonged activation of downstream ki-
B: RT-PCR analysis of transcripts present in K-ras/ MEFs, K-ras/V12; nases in the ras survival pathway. As illustrated in Figure 4C,
CMV-Cre/T MEFs, and K-ras/V12;CMV-Cre/T lung adenocarcinoma (adeca). EGF treatment of serum-starved primary K-ras/V12;CMV-Cre/T
Triangles indicate the SfcI DNA fragments (90 bp and 45 bp) diagnostic of
MEFs maintains detectable levels of phosphorylated Akt kinasethe oncogenic K-rasV12 allele.
for at least one hour, whereas in control MEFs, phosphorylated
Akt can no longer be detected 10 min after EGF exposure.
Sustained Akt activation may also contribute to loss of prolifera-
tive senescence of K-rasV12-expressing MEFs.Expression of an endogenous K-rasV12 oncogene
prevents proliferative senescence
K-rasV12-expressing MEFs senesce uponWe have followed two independent strategies to generate MEFs
oncogenic stressexpressing the oncogenic K-rasV12 allele. First, we obtained
Previous studies have indicated that primary MEFs enter a se-MEFs from E13.5 embryos derived from crosses between
nescence state upon oncogenic stress induced by ectopic ex-K-ras/V12 and CMV-Cre/T mice (Figure 3). CMV-Cre/T is a trans-
pression of ras oncogenes (Serrano et al., 1997). These senes-genic strain that express the Cre recombinase under the control
cent cells display permanent G1 arrest and are phenotypicallyof the CMV viral promoter (Schwenk et al., 1995). All E13.5
K-ras/V12;CMV-Cre/T embryos analyzed were mosaic for -geo indistinguishable from those undergoing proliferative senes-
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Figure 3. Summary of K-ras targeted mice used
in this study
Black boxes, K-ras coding sequences; white
boxes, K-ras noncoding sequences; Hyg, PGK-
Hygromycin cassette; STOP, transcriptional inhib-
itory sequences; IRESgeo, IRES--geo cassette;
pA, polyadenylation signal. Triangle, loxP sites.
V12, oncogenic mutation in codon 12 that results
in replacement of a glycine residue by valine.
Arrow, active K-ras transcription; X, impaired
K-ras transcription.
cence. Since MEFs expressing the K-rasV12 allele do not undergo sor proteins encoded by this locus. Likewise, these immortal
K-ras/V12;CMV-Cre/T MEFs retain a normal P53 pathway asproliferative senescence (Figure 4A), we investigated whether
this property could be due to loss of their senescence program. determined by their ability to respond to genotoxic damage. As
illustrated in Figure 5D, doxorubicin treatment of passage 25To this end, primary K-ras/V12;CMV-Cre/T MEFs were infected
with retroviruses carrying H-ras, K-ras4A, or K-ras4B onco- K-ras/V12;CMV-Cre/T MEFs results in the efficient induction of
both P53 and P21Cip expression (Figure 5D). These resultsgenes. As illustrated in Figure 5A, these MEFs undergo senes-
cence due to oncogenic stress even if they have overriden prolif- suggest that immortalization of MEFs expressing an endoge-
nous K-rasV12 oncogene does not involve loss of tumor suppres-erative senescence. Activation of the senescence program was
monitored by expression of their endogenous -galactosidase sor pathways frequently found responsible for the immortaliza-
tion of normal MEFs in culture.(data not shown) and overexpression of Ris1, the product of
the ras-induced senescence gene, m-ris1 (Figure 5B) (Barradas To investigate whether MEFs expressing the K-rasV12 onco-
gene contain other type of mutations such as chromosomalet al., 2002). These observations indicate that immortalization
induced by the endogenous K-rasV12 oncogene does not prevent abnormalities, we performed spectral karyotyping analysis
(SKY) of primary and late passage (p19) MEFs. Less than 5% ofsenescence induced by oncogenic stress. These findings sug-
gest that proliferative senescence and senescence induced by primary K-ras/;CMV-Cre/T and K-ras/V12;CMV-Cre/T MEFs
display chromosomal abnormalities despite the presence ofoncogenic stress involve different mechanisms.
the CMV-Cre transgene (Loonstra et al., 2001). However, as
K-ras/V12;CMV-Cre/T MEFs proliferate in culture, the numberTransformation of primary MEFs expressing
an endogenous K-rasV12 oncogene of chromosomal abnormalities increases substantially, reaching
up to 50% of the observed metaphases by passage 19. Abnor-K-ras/V12;CMV-Cre/T and K-ras/V12;RERTn/ERTOHT MEFs show
loss of contact inhibition, but do not display the typical morphol- malities include tetraploidity, reciprocal and unbalanced translo-
cations, deletions, acentric fragments, and dicentric fusions.ogy of transformed cells. Moreover, they do not grow in semi-
solid media and do not form tumors when injected into immuno- Parallel cultures of immortal (passage 19) K-ras/;CMV-Cre/T
MEFs only display tetraploid cells in 15% of the metaphasescompromised mice (data not shown). These MEFs are also
resistant to transformation by nuclear oncogenes such as ade- analyzed. These results suggest that immortalization induced
by expression of the oncogenic K-rasV12 allele may induce dereg-novirus E1A (Ruley, 1983) (Figure 5C). However, K-ras/V12;
CMV-Cre/T MEFs undergo morphologic transformation upon ulation of checkpoints responsible for maintaining chromosomal
stability, thus contributing to tumor development.cotransfection with exogenous K-ras and adenoviral E1A onco-
genes with efficiencies similar to that of wild-type MEFs (Figure
5C). Transformed K-ras/V12;CMV-Cre/T MEFs induce tumors Tumor development in K-ras/V12 mice
Crosses between K-ras/V12 and CMV-Cre/T transgenic micewhen injected in nude mice with an efficiency similar to wild-
type transformed MEFs (data not shown). These results indicate result in frequent embryonic lethality, presumably due to expres-
sion of the K-rasV12 oncogene during early development (un-that transformation of primary rodent cells requires the coopera-
tion of two oncogenes, providing that they are expressed at published data). However, a significant number of K-ras/V12;
CMV-Cre/T mice reach adulthood. These mice develop breath-high levels.
ing difficulties after seven to eight months of age (Figure 6, top
panel). Postmortem examination reveals a broad spectrum ofChromosomal abnormalities in late passage
K-rasV12-expressing MEFs multifocal lesions in lungs, ranging from small patches of bron-
chiolo-alveolar hyperplasias to large bronchiolo-alveolar adeno-Overcoming proliferative senescence often involves mutations
in either the INK4a or P53 loci. Late passage (p25) K-ras/V12; mas and adenocarcinomas that compress adjacent lung struc-
tures (Figures 6A–6D). These tumor cells express surfactantCMV-Cre/T MEFs retain a functional INK4a locus, at least as
determined by the normal levels of expression of both P16INK4a protein C (SPC), suggesting that they are derived from type II
pneumocytes (Figure 6E). Very occasionally, CC10 immuno-(not shown) and P19Arf (Figure 5D), the two tumor suppres-
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mutant mice, such as pituitary adenomas or hemangiosarcomas
(Sotillo et al., 2001), thus suggesting that K-RasV12 signaling in
these cells does not contribute to their tumorigenic phenotype
(see below). K-ras/V12;CMV-Cre/T;cdk4/R24C mice display focal
metaplasia in pancreatic ducts not observed in either parental
strain. This metaplasia consists of tall columnar cells with abun-
dant apical mucin, resembling gastric surface epithelial cells
(Figure 7). This abnormality closely resembles human mucinous
metaplasia (Chen et al., 1985), a preneoplastic lesion that often
contains K-ras oncogenes (Yanagisawa et al., 1993).
Controlled activation of the oncogene K-rasV12 allele
in postnatal mice
To activate expression of the K-rasV12 allele in somatic cells
in a temporally controlled manner, we submitted P10 K-ras/V12;
RERTn/ERT mice to systemic treatment involving limiting doses
of 4-OHT (0.1 mg, 3 times a week for 2 weeks). Exposure to
this synthetic steroid results in the activation of the inducible
Cre-ERT2 recombinase leading to removal of the STOP tran-
scriptional sequences that prevent expression of the targeted
K-rasV12 allele. X-Gal analysis of tissue sections two weeks after
4-OHT treatment revealed that 5% to 15% of cells in most
tissues expressed the -geo marker (data not shown). After
seven months of age (Figure 6, top panel), all treated mice
(n  9) developed breathing difficulties due to the presence of
multiple lesions in the lung, indistinguishable from those de-
scribed above. Southern blot analysis of DNA isolated from lung
adenomas reveals that these benign tumors maintain the wild-
Figure 4. Growth and signaling properties of MEFs expressing an endoge- type allele (data not shown), thus indicating that loss of thenous K-rasV12 oncogene
normal K-rasV12 allele is not a prerequisite, at least for the early
A: Growth curve of K-ras/ (black square), K-ras/V12 (black triangle),
stages of tumor development (Zhang et al., 2001). We have notK-ras/V12;CMV-Cre/T (white circle) and K-ras/V12;RERTn/ERTOHT (white square)
observed other areas of abnormal growth in these mice, withMEFs cultivated according to a 3T3 protocol. The y axis indicates the esti-
mated number of accumulated cells. the exception of hyperplastic Harderian glands.
B: Western blot analysis of the activation of Erk1/2 in proliferating primary Histological examination of other tissues obtained from
K-ras/, K-ras/V12, and K-ras/V12;CMV-Cre/T MEFs either not treated () or these mice reveals a similar percentage of -geo cells (5% totreated () with 50 ng/ml of EGF for 5 min.
15%) as in young mice immediately after 4OHT treatment. TheseC: Kinetic analysis of the activation of Erk1/2 and Akt kinases upon addition
of EGF (50 ng/ml) to serum-starved primary K-ras/;CMV-Cre/T and observations suggest that most cells expressing the oncogenic
K-ras/V12;CMV-Cre/T MEFs. Total Erk1/2 or Akt proteins serve as loading K-rasV12 allele do not have proliferative advantage. Indeed, a
controls. significant number of morphologically normal -geo cells, in-
dicative of K-rasV12 expression, could be identified in the bronchi-
olo-alveolar lung epithelia (Figure 8A). In other tissues, -geo
cells appear morphologically normal and within areas com-
staining revealed a few cells of Clara cell origin (Figure 6F). pletely devoid of any hyperplastic growth (Figures 8B–8H).
These results are similar to those recently reported in other These tissues include testicular seminiferous tubes (Figure 8B),
animal models expressing K-ras oncogenes (Jackson et al., epithelial cells of the renal Bowman’s capsules (Figure 8C), hair
2001; Johnson et al., 2001; Meuwissen et al., 2001). We have follicles in the dermis (some of these being completely made
also observed occasional foci of hyperplastic epithelial cells in up of -geo cells) (Figure 8D), the molecular layer of the cere-
nonrespiratory bronchioles (data not shown). Tumors other than bellum (Figure 8E), and liver hepatocytes (Figure 8F). Of particu-
lung adenomas also appear in these mice, including histiocytic lar interest is the presence of morphologically normal -geo
sarcomas (2/20), anal papillomas (3/20), and sarcomas (3/20). cells in the exocrine pancreas (Figure 8G), since most human
All tumors and hyperplastic regions invariably express the -geo pancreatic adenocarcinomas contain K-ras oncogenes (Almo-
marker (Figures 6A and 6B). Expression of the targeted K-rasV12 guera et al., 1988). Moreover, these mice contain a significant
allele was confirmed by RT-PCR analysis in selected samples number of intestinal crypts entirely formed by -geo cells (Fig-
(Figure 2B). ure 8H), suggesting that activation of the K-rasV12 oncogene has
We crossed K-ras/V12;CMV-Cre/T mice with cdk4R24C/R24C occurred in stem cells that retain their full potential to form these
knockin animals (Sotillo et al., 2001). K-ras/V12;CMV-Cre/T; crypts. These observations indicate that endogenous K-rasV12
cdk4/R24C mice develop multifocal lung adenomas with signifi- expression does not perturb the proliferation and/or differentia-
cantly shorter latency (Figure 6, top panel). These mice also tion programs of most cell types.
develop histiocytic sarcomas, anal papillomas, and sarcomas. We observed similar results in K-ras/V12;CMV-Cre/T mice
However, the presence of the activated K-rasV12 allele does not as well as in double mutant K-ras/V12;CMV-Cre/T;cdk4/R24C
animals (data not shown). These observations indicate that ex-accelerate the development of tumors characteristic of cdk4R24C
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Figure 5. Biological properties of K-rasV12-express-
ing MEFs
Upper panels: Oncogenic stress induces senes-
cence in K-rasV12-expressing MEFs.
A: Morphology of K-ras/V12;CMV-Cre/T MEFs in-
fected with vector alone or with retroviruses car-
rying the indicated oncogene.
B: Western blot analysis of Ris1 expression in
K-ras/;CMV-Cre/T and two independent
clones of K-ras/V12;CMV-Cre/T MEFs infected
with vector alone (V) or with a retrovirus carrying
an H-ras oncogene (R). -actin serves as loading
control.
Middle panel: Malignant transformation of
K-rasV12-expressing MEFs.
C: K-ras/V12-expressing MEFs can be transformed
by ectopic expression of cooperating adenovi-
ral E1A and K-ras oncogenes
Lower panel: Late passage K-ras/V12-expressing
MEFs retain a functional P53 pathway.
D: Western blot analysis of the expression of
P19Arf, P53, and P21Cip in K-ras/ MEFs as well
as in primary and late passage (p25) K-rasV12;
CMV-Cre/T MEFs either not treated () or
treated () with 0.5 g/ml of doxorubicin (Dox)
for 6 hr. MEFs derived from P53/ mice were
used as negative controls.
pression at physiological levels of even two distinct oncogenic EGF treatment, K-rasV12-expressing MEFs display a more sus-
tained signaling response than control MEFs in their down-proteins acting in convergent pathways is not sufficient to in-
duce unscheduled proliferation in most cell types. stream mitogenic (Raf/Mek/Erk) and survival (PI3K/Pdk/Akt)
pathways than control MEFs, a trait likely to contribute to their
immortal properties. However, expression of the oncogenicDiscussion
K-rasV12 allele at physiological levels is not sufficient to induce
morphologic transformation in vitro or tumorigenic propertiesExpression of ras oncogenes under the control of retroviral or
in vivo, even in the presence of a cooperating oncogene suchother highly active promoters in primary MEFs leads to G1 arrest
as E1A. Thus, it is likely that if expressed at physiological levels,and premature senescence due to oncogenic stress (Serrano
et al., 1997). Based on these observations, it was proposed that even rodent MEFs may need multiple mutations to acquire neo-
plastic properties.transformation by ras oncogenes requires abrogation of cellular
senescence programs, for instance by mutation of the P53 or Several in vivo models expressing K-ras oncogenes have
been recently described (Fisher et al., 2001; Jackson et al.,INK4a tumor suppressor pathways. Here, we show that expres-
sion of a targeted K-rasV12 oncogene under the control of its 2001; Johnson et al., 2001; Meuwissen et al., 2001). One of
these (Johnson et al., 2001) recapitulates more closely humanown promoter does not induce senescence, but rather hyper-
proliferative properties characteristic of immortal cells. Upon disease since it involves occasional activation of an endogenous
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that described by Jackson et al. (2001) in which transcription
of the targeted K-ras allele requires expression of Cre recombi-
nase. In our model, we have activated the K-rasV12 allele by
introducing either a CMV-Cre transgene that is expressed
throughout development or a knocked in inducible Cre-ERT2
recombinase that can be activated at any time in any cell type
by exposure to 4-OHT (V.C., N.M., C.G., and M.B., unpublished
data). In addition, our targeting strategy allows easy monitoring
of those cells expressing the targeted K-rasV12 oncogene by
staining for a marker protein (-geo) expressed from the same
K-rasV12 transcript by a bicistronic strategy.
K-ras/V12 mice carrying a CMV-Cre transgene develop lung
adenomas and adenocarcinomas with complete penetrance.
About one-third of the animals also develop additional tumors.
In contrast, when the targeted K-rasV12 allele is activated postna-
tally for a short period of time (2 weeks), we observe multifocal
lung adenomas and adenocarcinomas, but, so far, no other
tumor types. The main difference between these models is that
whereas intragenic recombination (Johnson et al., 2001) or
CMV-Cre-dependent activation (this work) may occur at any
time throughout embryonic or postnatal development, 4-OHT-
mediated activation of K-rasV12 only takes place for a short period
of time. These observations suggest that tumor development
induced by endogenous K-ras oncogenes is highly dependent
not only on the cell type, but also on their developmental and/
or differentiation state when activation occurs.
The inclusion of a marker protein in the knock in strategy
has allowed us to establish that expression of the targeted
K-rasV12 allele is not limited to those cells that undergo hyperplastic
growth or tumor development. On the contrary, K-ras/V12;
CMV-Cre/T and 4-OHT-treated K-ras/V12;RERTn/ERT mice ex-
press the oncogenic K-rasV12 allele in a wide range of cell types.
However, most of these cells do not display altered morpholo-
gies or hyperplastic properties. Examination of young K-ras/V12;
CMV-Cre/T or K-ras/V12;RERTn/ERT mice immediately after
4-OHT treatment reveals a similar percentage of -geo cells
in lungs as in other tissues in which no tumor development
occurs, even after eight months of life. Thus, the high suscepti-
Figure 6. Tumor development in mice expressing K-rasV12 transcripts bility of bronchiolo-alveolar cells to tumor development must be
Upper panel: Survival curve of K-ras/V12;CMV-Cre/T (white circle), K- ras/V12; due to an intrinsic consequence of their transcriptional program.
CMV-Cre/T;cdk4/R24C (black circle), and 4-OHT treated K-ras/V12;RERTn/ERT Whether this is due to a failure of the K-rasV12 oncogene to elicit
(black triangle) mice.
a mitogenic response or to activation of inhibitory pathways inLower panel: Bronchiolo-alveolar tumors in K-ras/V12;CMV-Cre/T mice.
these cells remains to be explored.A: Macroscopic view of the lung nodules after whole-mount X-Gal staining.
B: Paraffin section after X-Gal staining of a representative lung with multiple 4-OHT-treated K-ras/V12;RERTn/ERT mice contain a signifi-
adenomas from a K-ras/V12;CMV-Cre/T mouse. cant number of morphologically normal intestinal crypts, entirely
C: Alveolar architecture of small adenomas. made of -geo cells. These cells proliferate and differentiateD: Morphologic appearance of large adenomas.
normally despite expressing oncogenic K-rasV12 transcripts.E: SP-C immunostaining of a section showing an adenoma (black arrow)
These observations are in agreement with clinical studies thatand an adenocarcinoma (white arrow).
F: CC10 immunostaining of a section showing an adenoma (black arrow) suggest that activation of K-ras onogenes is not the primary
and a nonrespiratory bronchiole (white arrow). event in the development of human colon carcinomas (Oudejans
et al., 1991). Remarkably, tissues of double mutant K-ras/V12;
CMV-Cre/T;cdk4/R24C mice also contain a significant percent-
age of K-rasV12-expressing cells. These cells also contain a mu-K-ras oncogene by intragenic recombination in somatic cells.
tant Cdk4R24C kinase whose activity cannot be downregulatedThese mice develop lung adenocarcinomas with complete pen-
by INK4 inhibitors. However, none of these tissues display ab-etrance. Approximately one-third of these mice also develop
normal morphology or hyperproliferative properties, indicatingthymic lymphomas and skin papillomas, as well as aberrant
that most cell types tolerate a significant level of oncogenicintestinal crypt foci, but no colon tumors. However, this model
burden without neoplastic consequences. On the other hand,does not allow identification of those cells expressing the K-ras
coexpression of the mutant Cdk4R24C protein in bronchiolo-alve-oncogenes or the timing in which K-ras activation occurs, thus
olar cells susceptible to transformation by K-rasV12 significantlymaking it difficult to study the early stages of the disease.
In this study, we have used a targeting strategy similar to reduces tumor latency.
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Figure 7. Metaplasia in pancreatic ducts of
K-ras/V12;CMV-Cre/T;cdk4/R24C mice
A: Normal duct. Arrows indicate duct structures.
The asterisk indicates an islet.
B: Focal metaplasia in pancreatic ducts. Arrow
indicates a normal duct within this abnormal
structure.
C: Detailed columnar structure of metaplastic
cells with abundant apical mucin resembling
gastric surface epithelial cells.
DNA that encompasses the mouse 3UTR and a 400 bp SacI-StuI fragmentOur results strongly suggest that tumor susceptibility de-
of pCMV-K-ras DNA that contains the human noncoding exon 0 (Leon etpends to a great extent upon cellular context. Unveiling those
al., 1987). To target the 3 region of the K-ras locus, we generated a targetingpathways responsible for the dramatic differences in the re-
vector (pMCG26) by inserting the IRES--geo cassette (Mountford et al.,
sponse to K-rasV12 expression in the mice described here should 1994) into the XbaI site of a 7 Kb HindIII-SalI DNA fragment that encompasses
significantly improve our understanding of how neoplastic trans- the entire exon 4B. This XbaI site is located 560 bp downstream from the
formation occurs in vivo. TGA stop codon and 552 bp upstream from a putative polyadenylation site
likely to correspond to the 2 Kb K-ras transcript (Leon et al., 1987). To target
Experimental procedures the 5 region of the K-ras locus, we mutagenized two nucleotides (underlined)
corresponding to codon 12 (GGT [Gly] to GTA [Val]) in a plasmid containing
Targeting vectors the first K-ras exon within a 700 bp EcoRI DNA fragment. These mutations
K-ras genomic DNA clones were isolated from a 129/Sv genomic DNA library also create a diagnostic SfcI restriction site, CTGTAG. Selected clones were
sequenced to ensure that only the desired mutations were introduced. To(Stratagene) using as probes a 600 bp EcoRI-HindIII fragment of pSK-K-ras
Figure 8. -geo expression in several tissues of 4-OHT treated K-ras/V12;RERTn/ERT mice
X-Gal staining of representative paraffin sections depicting:
A: Lung bronchiolo-alveolar cells.
B: Testicular seminiferous tubes.
C: Bowman’s capsules in the kidney.
D: Hair follicles in the dermis.
E: Molecular layer of the cerebellum.
F: Liver hepatocytes.
G: Exocrine pancreas.
H: Intestinal crypts.
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generate the targeting vector (pMCG25), we inserted a PGK-Hyg-STOP oncogenes and selected in the presence of 2 g/ml of puromycin for 3 days
(Serrano et al., 1997). For transformation assays, we transfected primarycassette flanked by loxP sites within a 5 Kb NotI-EcoRV DNA fragment at
MEFs (passage 3) by the standard calcium chloride protocol with pMCV-an EcoRI site located 100 bp upstream of the mutagenized exon 1. This
E1A12S (Kraus et al., 1992) and pBABE-puro-K-rasAV12 or pBABE-puro-cassette had been previously generated by inserting a 1.8 Kb BglII DNA
K-rasBV12 DNAs. We scored foci of morphologically transformed cells afterfragment containing the hygromycin resistance gene (Hyg) under the control
20 days in culture. For tumorigenesis assays, foci were inoculated in theof the phosphoglycerolkinase (PGK) promoter (a gift of Dr. I. Sanchez-Garcı´a)
flank of nude mice (106 cells per flank). Mice were sacrificed when tumorsinto the BglII site of pBS302 (Gibco-BRL), a plasmid that contains the floxed
reached a diameter of 1 cm.STOP sequences.
Western blot analysisGeneration of knockin mice
Tissue samples or cultured cells were lysed in 50 mM Tris-HCl (pH 7.4)R1 ES cells (Nagy et al., 1993) were cultured in Dulbecco’s modified Eagle’s
containing 150 mM NaCl, 0.5% NP-40, and protease inhibitors. Extractsmedium (DMEM) supplemented with 15% heat inactivated fetal bovine serum
were separated by 12% or 15% SDS-PAGE, transferred to nitrocellulose(FBS) and 103 U/ml of leukemia inhibitory factor (LIF). 20 g of linearized
filters, and incubated with the corresponding antibodies including anti-ErkpMCG26 DNA were electroporated into 5.6  106 R1 cells in 0.8 ml at 240
(sc-94, Santa Cruz Biotechnology), anti-P-Erk, anti-P-Akt, anti-Akt (9019S,V and 500 F with a Genepulser (BioRad). Cells were grown for 7 days in
9271S, 9272, respectively, New England Biolabs), anti-Ris1, anti P19Arf200 g/ml of G418 (Sigma). G418-resistant clones were submitted to South-
(ab80, Abecam), anti-P53 (Ab3, Oncogene Research Products), anti-P21Cipern blot analysis to identify those that had undergone the expected recombi-
(sc-397G, Santa Cruz Biotechnology), and -actin (AC-15, Sigma). Antibod-nation event. Two clones (MCG224 and MCG231) were selected to target
ies were detected with the appropriate horseradish peroxidase-linked sec-the 5 region. To this end, 20 g of linearized pMCG25 DNA was electropor-
ondary antibody and visualized with enhanced chemioluminiscent (ECL)ated as described above. Cells were grown for 7 days in 200 g/ml hygro-
system (Amersham).
mycin and 2 M gancyclovir. DNA was isolated from double resistant clones
and submitted to Southern blot analysis. Spectral karyotyping (SKY)
Targeted ES cells carrying the two recombination events in the same Painting probes for each chromosome were generated from flow-sorted
allele were identified by X-Gal staining only after transfection with a plasmid mouse chromosomes using sequence-independent DNA amplification. La-
encoding a Cre recombinase. Positive clones were submitted to cytogenetic beling was performed by incorporating four different dyes in a combination
analysis and two of them (MCG537 and MCG758) among those exhibiting sequence that allows unique and differential identification of each chromo-
a normal karyotype were used to generate chimeric mice by microinjection some. To obtain mouse metaphases, MEF cultures were exposed to col-
into C57BL/6 blastocysts. Chimeric male mice were backcrossed to cemid for 3 hr, treated for 20 min in isotonic conditions (70 mM KCl), washed
C57BL/6 females and germline transmission of the targeted allele scored three times in Carnoy’s fixative (methanol:acetic acid, 3:1), and dropped into
by Southern blot analysis of tail DNA from the agouti offspring. glass slides. Prior to hybridization, chromosome spreads were treated with
pepsin (0.001% pepsin in 10 mM HCl, 37C). A mouse SKY probe mixture
PCR genotyping (Applied Spectral Imaging) was hybridized for 48 hr. Washing of preparations
For routine genotyping of K-ras/V12 mice, we submitted tail DNA to PCR and detection of probe was carried out according to the instructions of the
analysis at 94C for 5 min, followed by 30 cycles of 94C denaturing for 1 manufacturer. Chromosome spreads were counterstained with DAPI. Image
acquisition was performed with the SpectraCube system (Applied Spectralmin, 60C annealing for 1 min, and 72C extension for 1 min, followed by
Imaging) mounted on an Axioplan 2 microscope (Zeiss).an elongation cycle of 72C for 10 min with the following primers: 5 forward
primer (5I0, 5-AGGGTAGGTGTTGGGATAGC-3), reverse wild-type primer
Histological analysis, X-Gal staining, and immunohistochemistry(3Ex1, 5-CTCAGTCATTTTCAGCAGGC-3), and reverse mutant primer
Mice were sacrificed at the specified times or upon onset of visible disease.(103rev-2, 5-CTGCTCTTTACTGAAGGCTC-3). The sizes of the diagnostic
Tissue samples were fixed in 10% formalin and processed for hematoxylinPCR products are 403 bp for the wild-type allele and 621 bp for the targeted
and eosin (H&E) staining. X-Gal staining was performed as described (HoganK-ras allele. In tissues and MEFs in which the floxed STOP cassette present
et al., 1994). Counterstaining of paraffin sections was performed with nuclearin the targeted K-ras allele has been excised, primers 5I0 and 3Ex1 yield a
fast red. Antibodies against SP-C (AB3786, Chemicon) and CC10 (sc-9772,DNA fragment of 669 bp.
Santa Cruz Biotechnology) were used at a final dilution of 1:500.
RT-PCR analysis
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